Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -9.49
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ASMB)
- Company Assembly Biosciences, Inc.
- Price $16.58
- Changes Percentage (-2.36%)
- Change -$0.4
- Day Low $16.43
- Day High $17.38
- Year High $19.93
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $35.50
- High Stock Price Target $36.00
- Low Stock Price Target $35.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$10.58
- Trailing P/E Ratio -1.35
- Forward P/E Ratio -1.35
- P/E Growth -1.35
- Net Income $-61,228,000
Income Statement
Quarterly
Annual
Latest News of ASMB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Individual investors in Assembly Biosciences, Inc. (NASDAQ:ASMB) are its biggest bettors, and their bets paid off as stock gained 14% last week
21 investors collectively own 50% majority stake in Assembly Biosciences, Inc. Individual investors hold the largest share, followed by institutional investors and hedge funds. The company's largest s...
By Yahoo! Finance | 2 months ago
